VRD GmbH
VC Fund
Heidelberg, Germany
VRD GmbH is a VC fund in Heidelberg focused on Food and Beverage and Fitness. They are the family office of a traditional family business.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries VRD GmbH invests in
Food and BeverageFitnessE-CommerceHealth CareBiotechnology
Stages VRD GmbH invests in
SeedSeries ASeries HFunding RoundVenture - Series Unknown
Countries VRD GmbH invests in
GermanyAustraliaUnited Kingdom
Round sizes
Seed $5.9M–$11MSeries H $2.4M–$4.7M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $5.9M–$11M
- Series H
- $2.4M–$4.7M
Investment Focus
Industry
- Food and Beverage 2 (20%)
- Fitness 1 (10%)
- E-Commerce 1 (10%)
- Health Care 1 (10%)
- Biotechnology 1 (10%)
Stage
- Seed 3 (30%)
- Series A 1 (10%)
- Series H 1 (10%)
- Funding Round 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- Germany 2 (20%)
- Australia 1 (10%)
- United Kingdom 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Abe Abe Gong
Co-Founder & CEO
|
Co-Founder & CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SUSHI Bikes has developed the perfect e-bike for modern urban people. | Seed / Jul 12, 2023 | ||
| Mighty Pea is a pea milk producer, which uses yellow split peas in the creation of its beverages. | $5.9M / Seed / Dec 08, 2021 | ||
| Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $26.8M / Series A / Nov 15, 2021 | ||
| Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $6.9M / Seed / May 04, 2021 | ||
| Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $9M / Seed / May 01, 2021 | ||
| Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen. | $11.2M / Seed / Sep 25, 2020 | ||
| Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $2.4M / Series H / Mar 18, 2017 | ||
| Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $4.7M / Series H / Jul 26, 2016 | ||
| Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $2.8M / Venture - Series Unknown / May 08, 2014 | ||
| See all 10 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
48,627 investors
Marketplace Investors
48,297 investors
Gaming Investors
32,180 investors
Biotech Investors
24,131 investors
Biotechnology Investors
21,397 investors
Food and Beverage Investors
16,903 investors
Fitness Investors
7,542 investors
Health Care VC Funds
36,465 investors
Marketplace VC Funds
31,531 investors
FAQ
What does VRD GmbH invest in?
VRD GmbH invests primarily in Food and Beverage, Fitness and E-Commerce startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is VRD GmbH's check size?
VRD GmbH typically joins rounds of $5.9M–$11M at Seed and $2.4M–$4.7M at Series H. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds VRD GmbH participates in.
How do I contact VRD GmbH?
Public channels for VRD GmbH include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at VRD GmbH?
The team at VRD GmbH includes Abe Abe Gong (Co-Founder & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
